Clear Search

Showing 84 results for “SLE”.

May 2024

Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)

Rheumatol. Int. 2024 Apr 30:1–7 DOI: 10.1007/s00296-024-05589-2 https://pubmed.ncbi.nlm.nih.gov/38687385/

Belimumab confers an early and sustained corticosteroid-sparing effect after 3 months of treatment in SLE patients. This was demonstrated by a significant prednisone dose reduction that continued through months 6 and 12, and was sustained until month 24.

more…

April 2024

Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis

Lupus Sci Med 2024;11(1):e001152 DOI 10.1136/lupus-2024-001152

Patients with SLE and LN show increased risk of CV risk factors including diabetes mellitus, hypertension and hyperlipidaemia versus patients without nephritis.

more…

CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up

N Engl J Med 2024;390(8):687–700 DOI 10.1056/NEJMoa2308917

In this case series by Müller, et al., eight patients who received a CD19 CAR T-cell infusion achieved Definition of Remission in SLE (DORIS) remission, Lupus Low Disease Activity State and a SLEDAI 2K score of 0 at 6 months post-infusion. Long-term follow-up through 24 months showed that SLE disease activity remained absent
in all eight patients.

more…

March 2024

Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up

Rheumatology 2024 DOI 10.1093/rheumatology/keae120 Epub ahead of print

Patients with a lupus low disease activity state (LLDAS) irrespective of organ damage were significantly more likely to have favourable health-related quality of life, pain, fatigue, and overall health experience.

more…

TYK2: An emerging therapeutic target in rheumatic disease

Nat Rev Rheumatol 2024;20(4):232–40 DOI 10.1038/s41584-024-01093-w

TYK2 inhibitors hold promise for the treatment of a distinct spectrum of autoimmune diseases, including SLE, and could potentially have a safety profile that differs from other JAK inhibitors.

more…

February 2024

Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken). 2024 doi: 10.1002/acr.25301. Epub ahead of print.

Expert workgroup members and patient partners recommend that clinicians assess depression and physical function at least once yearly in all people with SLE. Additional patient reported outcome measures addressing cognition and fatigue can also be assessed.

more…